Epirubicin and ifosfamide in advanced soft tissue sarcomas
نویسندگان
چکیده
منابع مشابه
Ifosfamide with regional hyperthermia in soft-tissue sarcomas.
For high-risk soft tissue sarcomas (HR-STS) of adults, new treatment strategies are needed to improve outcome with regard to local control and overall survival. Therefore, systemic chemotherapy has been integrated either after (adjuvant) or before (neoadjuvant) optimal local treatment by surgery and radiotherapy in HR-STS. The combination with regional hyperthermia as a new treatment strategy s...
متن کاملA Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS)
PURPOSE The aim of this study was to determine the efficacy and safety of docetaxel plus epirubicin combination as first-line chemotherapy in patients with locally advanced and/or metastatic adult STS. PATIENTS AND METHODS Eighteen patients were treated with epirubicin 30 mg/m(2) on days 1 to 3 and docetaxel 100 mg/m(2) on day 1 every 3 weeks. RESULTS Fifteen out of 18 patients (83.4%) were...
متن کاملSystemic Therapy for Advanced Soft Tissue Sarcomas
Soft tissue sarcomas (STS) are a rare, heterogeneous group of solid tumors in need of improved therapeutic options. First-line chemotherapy is considered the current standard of care for patients with advanced, symptomatic STS, but the median survival is only 8 to 12 months. Efforts to increase response rates by using combination or dose-dense regimens have largely failed to improve patient out...
متن کاملneoadjuvant chemotherapy with ifosfamide, cisplatin, adriamycin and mitomycin (imap) for high risk adult soft tissue sarcomas
to define efficacy of pre-operative chemotherapy in down staging of advanced non-round cell soft tissue sarcomas. from sep 2002 to dec 2005, 70 patients were treated by ifosfamid, mesna, cisplatin, adriamycin, mitomycin and subsequent surgery. postoperatively, patients received radiotherapy in cases of microscopically incomplete resection or local recurrence. the median age of the patients was ...
متن کاملIfosfamide in soft tissue sarcoma.
Ifosfamide, a congener of Cyclophosphamide, was originally introduced into clinical practice in 1971, but has not been widely used because of severe dose limiting urotoxicity, particularly when used as a single agent in large doses. A resurgence of interest in Ifosfamide followed the demonstration that urotoxicity could be lessened or abrogated by fractionated administration or, more effectivel...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 1993
ISSN: 0923-7534
DOI: 10.1093/oxfordjournals.annonc.a058622